Interim Safety Analysis Supports Continuation of Neuren's Phase 3 Glypromate® Trial

- Independent review of safety and adverse event data on the first 100 patients recommends continuation of Glypromate® Phase 3 trial
- Recruitment in Phase 3 trial on track as planned with 258 patients enrolled to date
- Expect to complete enrollment in the fourth quarter of 2008

**SYDNEY Australia 15 May 2008:** Neuren Pharmaceuticals (ASX: NEU) today announced that a pre-specified Data Safety Monitoring Committee (DSMC) review of clinical data from the first 100 patients participating in the Phase 3 trial of its lead compound, Glypromate®, recommended that the trial continue in line with its protocol.

Leading neurologist and chairman of the independent DSMC, Professor Graeme Hankey, reported that a detailed review of patient data showed “no difference in adverse events or other measures of safety between the treated and untreated patient populations”.

Neuren joint-CEO Dr Parmjot Bains said 250 patients had been recruited into the Phase 3 trial to date and that the trial was on track for completion of enrollment this year.

Glypromate® is being developed to reduce cognitive impairment following cardiac surgery with cardiopulmonary bypass which affects up to 70 percent of patients at discharge. Approximately one-third of patients still exhibit cognitive impairment three months following surgery. More than one million cardiac bypass procedures are performed worldwide annually but there is no treatment approved to reduce or prevent cognitive impairment.

The DSMC will review patient data again at 300 completed patients in the third quarter of 2008. The reviews will involve a comprehensive safety assessment without unblinding the data. The review will also determine statistical variance of the endpoints on unblinded data to validate that the targeted sample size is appropriate.

In early 2007 Neuren filed an Investigational New Drug (IND) application and the US Food & Drug Administration (FDA) has confirmed the status of the trial as a major efficacy (pivotal) study. As a result, only one additional Phase 3 trial would be required for registration purposes.

**About Neuren**

Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury and diseases and metabolic disorders. The Neuren portfolio comprises eight product families targeting markets with large unmet needs and limited competition. Neuren has three lead candidate molecules — Glypromate®, Motiva™ and NNZ-2566—focused on a range of acute and chronic neurological conditions. For more information visit [www.neurenpharma.com](http://www.neurenpharma.com)

*For more information please contact: Dr Parmjot Bains, CEO Neuren (Australasia) T: +61 488 494 353 or Andrew Geddes T: +61 408 677 734*